Pure Global
NCT06419686

The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals
University Hospital, Gentofte, Copenhagen·Phase 1·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Effect of iv Administration of GIP and Alanine
Drug/Device/Intervention
Placebo (saline)
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University Hospital, Gentofte, Copenhagen
Location
Hellerup, Denmark
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2024
End date
Jul 01, 2024
Enrollment
10 participants
Primary outcome

Plasma concentrations of Glucagon,Plasma concentrations of Glucagon

Summary

The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10
 healthy male participants. Each participant will undergo four separate study days in
 randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either
 placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine.
 
 The primary objective of the study is to find out whether intravenous administration of the
 naturally occuring gut hormone GIP and the amino acid alanine, separately and combined,
 results in additive or synergistic glucagonotropic effects during euglycaemic conditions in
 healthy participants. Secondary objectives are to disclose the effect of the abovementioned
 interventions on insulin secretion and circulating levels of total and individual amino
 acids.

ICD-10 classifications
Poisoning: Other and unspecified hormone antagonistsPoisoning: Angiotensin-converting-enzyme inhibitorsPoisoning: 4-Aminophenol derivativesOther and unspecified hormone antagonistsOther agents primarily affecting the gastrointestinal system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419686
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419686 through Pure Global AI's free database. This Phase 1 trial is sponsored by University Hospital, Gentofte, Copenhagen and is currently Recruiting. The study focuses on Effect of iv Administration of GIP and Alanine. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.